骨髓干细胞移植治疗肝细胞癌的研究进展

Research progress on the treatment of hepatocellular carcinoma by transplanting bone marrow stem cells

肝细胞癌(HCC)是指原发于肝细胞的恶性肿瘤,占原发性肝癌的91.5%。目前肝细胞癌的治疗方法很多,其中骨髓干细胞(BMSCs))移植是肝细胞癌治疗的热点之一。BMSCs可促进肝组织再生,减缓肝硬化进程并诱导HCC凋亡。同时,BMSCs可以通过自分泌和旁分泌的方式改变HCC周围的微环境,从而抑制HCC向肝外组织的转移。随着分子生物技术的不断进步,BMSCs由于易于分离、体内扩增及进行基因修饰,已成为基因治疗的理想靶向细胞。然而,随着研究的深入,BMSCs的致瘤性风险也受到研究者的重视。本研究从BMSCs对肝癌组织及其转移的影响,BMSCs作为理想靶向细胞应用于基因治疗及BMSCs致瘤性的可能风险等方面的研究进展做一综述。

Hepatocellular carcinoma （HCC） refers to the primary liver cell malignant tumor, which is 91.5%of prima-ry liver cancer. Recurrently there are many methods of treating HCC and bone marrow stem cells （BMSCs） transplanta-tion is one of the hot spot on treating HCC. BMSCs can promote liver regeneration, slow down the process of cirrhosis and induce the apoptosis of HCC. At the same time, BMSCs can change the surrounding microenvironment of HCC by autocrine and paracrine, thus inhibiting HCC metastasis. Along with the advance of molecular biotechnology, BMSCs has become the ideal target cells of gene therapy due to the fact that BMSCs are esay to be isolated, expanded in vivo and genetically modified, which has become the ideal target cells of gene therapy. However, with the deepening of re-search, the tumorigenicity risk of BMSCs is also brought to the attention of researchers. This study does a review from BMSCs in liver cancer tissue and its transfer, the influence of BMSCs as the ideal target cells used in gene therapy and possible risk of progression of tumorigenicity by BMSCs.